Lupin is currently trading at Rs. 2302.70, up by 54.00 points or 2.40% from its previous closing of Rs. 2248.70 on the BSE.
The scrip opened at Rs. 2288.30 and has touched a high and low of Rs. 2,305.75 and Rs. 2271.85 respectively. So far 2493 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2492.00 on 07-May-2026 and a 52 week low of Rs. 1838.65 on 06-Aug-2025.
Last one week high and low of the scrip stood at Rs. 2,492.00 and Rs. 2,210.80 respectively. The current market cap of the company is Rs. 102817.88 crore.
The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 47.03% and 6.11% respectively.
Lupin has received approval from the United States Food and Drug Administration (USFDA) for its ranibizumab, Ranluspec (ranibizumab-hkdz), as an interchangeable biosimilar referencing to Lucentis (Genentech). Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes (PFS). Both the vial and PFS presentations are approved in both strengths available for Lucentis, 0.3 mg (0.05 mL of 6 mg/mL), and 0.5 mg (0.05 mL of 10 mg/mL).
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. It is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
